Literature DB >> 2872974

Therapeutic response to taxol of six human tumors xenografted into nude mice.

J Riondel, M Jacrot, F Picot, H Beriel, C Mouriquand, P Potier.   

Abstract

To test the antineoplastic activity of taxol, a natural product isolated from yew (Taxus baccata L.), six human tumors transplanted into athymic mice were used (primary tumors of breast, endometrium, ovary, brain, lung and a recurrence of tongue tumor). While the growth rates varied with the histopathological characteristics of different tumor types, all mice were treated at a mean tumor volume of 200 +/- 8 mm3. Taxol was given SC at a dose level of 12.5 mg/kg per injection per day for 5 consecutive days out of 7 over a period of 3 weeks. With this schedule antitumor responses were obtained in all of the six neoplasms xenografted into nude mice. In the case of the ductal carcinoma of the breast total tumor regressions were observed in four of the five treated animals. In the five other experimental models taxol produced significant growth delays. We believe that the results of these initial tests on the nude mouse--human tumor xenograft system are convincing and justify clinical assessment of this drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872974     DOI: 10.1007/bf00306742

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  New natural products of interest under development at the National Cancer Institute.

Authors:  J Douros; M Suffness
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison.

Authors:  D A Fuchs; R K Johnson
Journal:  Cancer Treat Rep       Date:  1978-08

3.  Taxol-induced anaphase reversal: evidence that elongating microtubules can exert a pushing force in living cells.

Authors:  A S Bajer; C Cypher; J Molè-Bajer; H M Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

4.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors:  P B Schiff; S B Horwitz
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

5.  Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores.

Authors:  M De Brabander; G Geuens; R Nuydens; R Willebrords; J De Mey
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

6.  Therapeutic response of human tumor xenografts in athymic mice to doxorubicin.

Authors:  F C Giuliani; K A Zirvi; N O Kaplan
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

7.  Correlation between response to chemotherapy of human tumors in patients and in nude mice.

Authors:  B C Giovanella; J S Stehlin; R C Shepard; L J Williams
Journal:  Cancer       Date:  1983-10-01       Impact factor: 6.860

8.  Human tumor xenografts in athymic (nude) mice: chemotherapy trials in serially transplanted tumors.

Authors:  H A Azar; S B Fernandez; L M Bros; J L Sullivan
Journal:  Ann Clin Lab Sci       Date:  1982 Jan-Feb       Impact factor: 1.256

9.  Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.

Authors:  S C Schold; D D Bigner
Journal:  Cancer Treat Rep       Date:  1983-09

10.  A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs).

Authors:  R B Vallee
Journal:  J Cell Biol       Date:  1982-02       Impact factor: 10.539

View more
  16 in total

1.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Authors:  J S Lanni; S W Lowe; E J Licitra; J O Liu; T Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Synergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors.

Authors:  Mark E Stearns; Min Wang
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

3.  Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice.

Authors:  Jin-Hui Yuan; Ru-Ping Zhang; Ru-Gang Zhang; Li-Xia Guo; Xing-Wang Wang; Dan Luo; Yong Xie; Hong Xie
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

4.  Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.

Authors:  M J Kelner; T C McMorris; L Estes; W Wang; K M Samson; R Taetle
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer.

Authors:  C A Jamis-Dow; R W Klecker; G Sarosy; E Reed; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Mathematical models of breast and ovarian cancers.

Authors:  Dana-Adriana Botesteanu; Stanley Lipkowitz; Jung-Min Lee; Doron Levy
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-06-03

Review 8.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

9.  Antioxidant status and lipid peroxidation in athymic mice xenografted with two types of human tumors.

Authors:  A S Gauchez; J Riondel; M Jacrot; J Calop; A Favier
Journal:  Biol Trace Elem Res       Date:  1995 Jan-Mar       Impact factor: 3.738

Review 10.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.